skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Use of electronic brachytherapy to deliver postsurgical adjuvant radiation therapy for endometrial cancer: a retrospective multicenter study

Original Research

(1760) Views  (333) Full article downloads

Authors: William C Dooley, John P Thropay, Gary J Schreiber, et al

Published Date September 2010 Volume 2010:3 Pages 197 - 203
DOI: http://dx.doi.org/10.2147/OTT.S13593

William C Dooley1, John P Thropay2, Gary J Schreiber3, Mohamed Y Puthawala4, Steven C Lane5, James C Wurzer6, Charles E Stewart7, Gordon L Grado8, Harish G Ahuja9, Gary M Proulx10
1University of Oklahoma Health Sciences Center, Oklahoma City, OK; 2Beverly Oncology and Imaging Center, Montebello, CA; 3Swedish Covenant Medical Center, Chicago, IL; 4Rhode Island Hospital, Providence, RI; 5Signature Healthcare Brockton Hospital, Brockton, MA; 6AtlantiCare Regional Medical Center, Egg Harbor Township, NJ; 7St Francis Medical Center, Tulsa, OK; 8Southwest Oncology Centers, Scottsdale, AZ; 9Aspirus Regional Medical Center, Wausau, WI; 10Exeter Hospital, Exeter, NH, USA

Background: This retrospective, multicenter study evaluated the feasibility and safety of high-dose rate electronic brachytherapy (EBT) as a postsurgical adjuvant radiation therapy for endometrial cancer.
Methods: Medical records were reviewed from 41 patients (age 40–89 years) with endometrial cancer (Federation of International Gynecology and Obstetrics stages IA–IIIC) treated at nine centers between April 2008 and October 2009. Treatment included intracavitary vaginal EBT alone (n = l6) at doses of 18.0–24.0 Gy in 3–4 fractions and EBT in combination with external beam radiation therapy (EBRT, n = 25) at a total radiation dose range of 40.0–80.4 Gy. Doses were prescribed to a depth of 5 mm from the applicator surface and to the upper third (n = 15) and the upper half (n = 26) of the vagina.
Results: Median follow-up was 3.8 (range 0.5–12.0) months. All 41 patients received the intended dose of radiation as prescribed. Adverse events occurred in 13 of 41 patients and were mild to moderate (Grade 1–2), consisting primarily of vaginal mucositis, rectal mucosal irritation and discomfort, and temporary dysuria and diarrhea. There were no Grade 3 adverse events in the EBT-only treatment group. One patient, who was being treated with the combination of EBT and EBRT for recurrent endometrial cancer, had a Grade 3 adverse event. No recurrences have been reported to date.
Conclusion: Electronic brachytherapy provides a feasible treatment option for postoperative adjuvant vaginal brachytherapy as sole radiation therapy and in combination with EBRT for primary endometrial cancer. Early and late toxicities were mild to moderate.

Keywords: endometrial cancer, electronic brachytherapy, radiation therapy




 

Other articles by Dr William Dooley



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Profile of temsirolimus in the treatment of advanced renal cell carcinoma
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
Electronic brachytherapy as adjuvant therapy for early stage breast cancer: a retrospective analysis
Zinc oxide nanoparticles as selective killers of proliferating cells
Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy